EE04453B1 - Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena - Google Patents

Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena

Info

Publication number
EE04453B1
EE04453B1 EE9700255A EE9700255A EE04453B1 EE 04453 B1 EE04453 B1 EE 04453B1 EE 9700255 A EE9700255 A EE 9700255A EE 9700255 A EE9700255 A EE 9700255A EE 04453 B1 EE04453 B1 EE 04453B1
Authority
EE
Estonia
Prior art keywords
beta
activating agent
lymphotoxin
lhc
carrier
Prior art date
Application number
EE9700255A
Other languages
English (en)
Estonian (et)
Other versions
EE9700255A (et
Inventor
L. Browning Jeffrey
Meier Werner
D. Benjamin Christopher
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE9700255A publication Critical patent/EE9700255A/xx
Publication of EE04453B1 publication Critical patent/EE04453B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EE9700255A 1995-01-26 1996-01-26 Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena EE04453B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26
PCT/US1996/001386 WO1996022788A1 (en) 1995-01-26 1996-01-26 LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

Publications (2)

Publication Number Publication Date
EE9700255A EE9700255A (et) 1998-04-15
EE04453B1 true EE04453B1 (et) 2005-04-15

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700255A EE04453B1 (et) 1995-01-26 1996-01-26 Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena

Country Status (24)

Country Link
EP (2) EP1407781A1 (de)
JP (2) JPH10513161A (de)
KR (2) KR100470739B1 (de)
CN (3) CN1900116A (de)
AT (1) ATE268604T1 (de)
AU (1) AU725351B2 (de)
BG (1) BG62599B1 (de)
BR (1) BR9606808A (de)
CA (1) CA2211443A1 (de)
CZ (1) CZ298711B6 (de)
DE (1) DE69632681T2 (de)
DK (1) DK0809510T3 (de)
EA (1) EA000096B1 (de)
EE (1) EE04453B1 (de)
ES (1) ES2220972T3 (de)
FI (1) FI119359B (de)
HU (1) HUP9801746A3 (de)
NO (1) NO322744B1 (de)
NZ (1) NZ303405A (de)
PL (1) PL185364B1 (de)
PT (1) PT809510E (de)
RO (1) RO118634B1 (de)
SK (1) SK286497B6 (de)
WO (1) WO1996022788A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
IL142284A0 (en) 1998-10-09 2002-03-10 Biogen Inc A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor
TR200300478T2 (tr) * 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
EP1539793A4 (de) * 2002-07-01 2006-02-01 HUMANISIERTE ANTI-LYMPHOTOIN-BETA-REZEPTOR-ANTIKöRPER
RS20050481A (sr) * 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (de) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
SG178002A1 (en) 2006-10-20 2012-02-28 Biogen Idec Inc Treatment of demyelinating disorders
MX2011003352A (es) * 2008-09-30 2011-05-02 Genentech Inc Marcadores biologicos predictivos de la respuesta de la artritis reumatoide a antagonistas de linfotoxina.
AU2012348017A1 (en) * 2011-12-05 2014-07-03 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
EP4255929A2 (de) 2020-12-02 2023-10-11 Vib Vzw Ltbr-agonist in kombinationstherapie gegen krebs
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
JPS61277628A (ja) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd 癌治療用白血球刺激材
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
ES2157889T3 (es) * 1990-06-27 2001-09-01 Biogen Inc Linfotoxina complejada de superficie.
AU692146B2 (en) * 1990-06-27 1998-06-04 Biogen Idec Ma Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof

Also Published As

Publication number Publication date
FI973118A0 (fi) 1997-07-25
HUP9801746A3 (en) 2000-11-28
KR100475492B1 (ko) 2005-03-14
CA2211443A1 (en) 1996-08-01
CN1177302A (zh) 1998-03-25
DE69632681T2 (de) 2005-06-09
CN1900116A (zh) 2007-01-24
HK1006356A1 (en) 1999-02-26
AU4970496A (en) 1996-08-14
JPH10513161A (ja) 1998-12-15
EA000096B1 (ru) 1998-08-27
SK286497B6 (sk) 2008-11-06
PL321758A1 (en) 1997-12-22
EA199700144A1 (ru) 1997-12-30
WO1996022788A1 (en) 1996-08-01
FI973118A7 (fi) 1997-09-25
ATE268604T1 (de) 2004-06-15
EP0809510A1 (de) 1997-12-03
NO973385D0 (no) 1997-07-22
CN1146442C (zh) 2004-04-21
EP0809510B1 (de) 2004-06-09
KR100470739B1 (ko) 2005-09-02
KR20040102364A (ko) 2004-12-04
BG62599B1 (bg) 2000-03-31
CN1589902A (zh) 2005-03-09
CZ236197A3 (cs) 1998-02-18
BG101855A (en) 1998-04-30
CZ298711B6 (cs) 2008-01-02
HUP9801746A2 (hu) 1998-11-30
MX9705629A (es) 1997-10-31
EE9700255A (et) 1998-04-15
AU725351B2 (en) 2000-10-12
PL185364B1 (pl) 2003-04-30
ES2220972T3 (es) 2004-12-16
NO322744B1 (no) 2006-12-04
JP2007169296A (ja) 2007-07-05
PT809510E (pt) 2004-09-30
RO118634B1 (ro) 2003-08-29
KR19980701816A (ko) 1998-06-25
DE69632681D1 (de) 2004-07-15
SK98697A3 (en) 2000-02-14
EP1407781A1 (de) 2004-04-14
DK0809510T3 (da) 2004-10-04
NO973385L (no) 1997-09-25
FI119359B (fi) 2008-10-31
BR9606808A (pt) 1997-12-30
NZ303405A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
EE9700255A (et) Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ß retseptori antikehad kasvajavastaste agensitena
Smith et al. Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid
Goldenberg et al. Evidence for a transport carrier of nitrogen mustard in nitrogen mustard-sensitive and-resistant L5178Y lymphoblasts
AU2332188A (en) Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors
KIRKPATRICK et al. Stereospecific glucocorticoid binding to subcellular fractions of the sensitive and resistant lymphosarcoma P1798
YU83600A (sh) Adenozin a3 receptorski modulatori
NO961706L (no) Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme
MX9709324A (es) Compuestos terapeuticos que comprenden anticuerpos anti receptores fc.
AU9779498A (en) Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
Gonzalez et al. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells
BR0015110A (pt) Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
AU9028498A (en) System, method and cassette for mixing and delivering intravenous drugs
ES2004395A6 (es) Procedimiento de obtencion de un sistema de vehiculo disolvente de doble fase, para compuestos farmaceuticamente activos.
CA2298018A1 (en) Methods and compositions for inhibiting angiogenesis
AU5465694A (en) Determination of peptide motifs on mhc molecules
NO20000576D0 (no) Blanding og fremgangsmåte for regulering av celleproliferasjon og celledoed
WO1991011201A3 (en) Compounds
EP1144666A3 (de) Replikation -defektive baculoviren expressionssystem
WO2002053195A3 (en) System for, and method of, irradiating article with x-ray beam
Gaut et al. Inhibition of nicotinate phosphoribosyl transferase by nonsteroidal anti-inflammatory drugs: A possible mechanism of action
Gulp et al. Transfer ribonucleic acid methylases of HeLa cells
De Bellis et al. In vitro studies of histone glycation
Maassen et al. Comparison by photoaffinity labeling of the proteins involved in GTP hydrolysis from 70S ribosomes and a 5S RNA-protein complex from bacillus stearothermophilus
WO1996012508A3 (en) Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy

Legal Events

Date Code Title Description
HK1A Erratum in gazette
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20100126